Table 2 Clinical features of the 152 epithelial ovarian cancer (EOC) patients involved grouped by training set and validation set.

From: Development and validation for prognostic nomogram of epithelial ovarian cancer recurrence based on circulating tumor cells and epithelial–mesenchymal transition

Variables Total (n = 152) Training group (n = 114) Validated group (n = 38) p-value
CTC counts (n/5 mL) 8.70 ± 5.69 8.64 ± 5.38 8.72 ± 4.65 0.935
M-CTC (n %) 0.24 ± 0.19 0.25 ± 0.21 0.22 ± 0.14 0.413
E-CTC (n %) 0.57 ± 0.25 0.56 ± 0.17 0.59 ± 0.23 0.392
Hybrids-CTC (n %) 0.19 ± 0.11 0.21 ± 0.18 0.20 ± 0.14 0.755
Neutrophil (109/L) 5.22 ± 2.91 4.67 ± 2.83 5.31 ± 1.96 0.198
lymphocyte (109/L) 1.42 ± 0.63 1.46 ± 0.85 1.37 ± 0.77 0.564
Platelet (109/L) 320.39 ± 78.68 299 ± 73.94 314 ± 80.21 0.291
Albumin (g/L) 40.49 ± 6.58 38.27 ± 9.38 41.22 ± 10.02 0.101
CA-125 (U/mL) 990.71 ± 365.41 1001.23 ± 330.98 986.53 ± 310.27 0.810
CA-199 (U/mL) 129.03 ± 53.18 121.88 ± 48.27 132.5 ± 59.12 0.270
AFP (ng/mL) 6.21 ± 4.78 6.43 ± 5.99 5.93 ± 3.45 0.627
CEA (ng/mL) 3.02 ± 2.57 2.95 ± 2.60 3.21 ± 2.47 0.589
HE4 (pmol/L) 536.12 ± 54.48 542.32 ± 79.39 521.39 ± 62.10 0.141
  1. CTC circulating tumor cell, M-CTC mesenchymal CTCs/ total CTCs percentage, E-CTC epithelial CTCs/ total CTCs percentage, Hybrids-CTC hybrids CTCs/ total CTCs percentage, CA-125 carbohydrate antigen-125, CA-199 carbohydrate antigen-199, CEA carcinoembryonic antigen, AFP alpha-fetoprotein, HE4 human epididymis protein 4.